J

Johnson & Johnson

Makes prescription drugs and medical devices

Territory Account Manager-AESS

Full-TimeUpdated on 10/23/2026
No salary listed
Junior
Bachelor's
Hyderabad, Telangana, India
In PersonField-based territory role in Hyderabad.
Sales & Account ManagementField Sales

About the job

Requirements
  • A science graduate qualification is required.
  • Preferably, candidates have 2 or more years of experience in healthcare.
  • At least 1 year of experience selling medical devices is required.
  • Sales experience selling laparoscopy products in key accounts is required.
Responsibilities
  • Sell franchise products within a territory and specialty and achieve sales targets.
  • Lead specialty-focused market development activities in the region.
  • Support other team members to ideate and execute specialty-focused initiatives.
  • Provide weekly and monthly sales action plans to the manager, reflecting the activities required in each account to achieve sales objectives.
  • Analyze sales reports to find opportunities, recognize routine problems, analyze causes, and recommend solutions.
  • Negotiate and close sales in routine situations, and handle more complex deals with guidance.
  • Participate in trade displays and conferences when required.
  • Develop an understanding of customer needs to identify sales opportunities.
  • Identify tender and contract opportunities and work with colleagues to deliver them.
  • Develop an effective and efficient territory plan with guidance.
  • Work with distributors and ensure they act as brand ambassadors for the products.
  • Identify and train surgeons on new technologies and solutions through consult-in-surgery, one-on-one sales calls, and one-to-many training sessions.
  • Work with the manager to identify customer in-service needs that support customer-delivered healthcare services and efficient and effective product use.
  • Develop and maintain strong relationships with all levels of customers.
  • Coordinate and deliver in-service education sessions with assistance.
  • Advise marketing on customers' in-service education resource needs.
  • Maintain expert knowledge of product features, benefits, correct product application and usage, anatomy, physiology, and medical procedures through practical experience, training programs, and learning from key end users.
  • Maintain thorough information on competitors' structure, culture, manpower, distribution, capabilities, and weaknesses.
  • Analyze market trends, identify threats and opportunities, and recommend and implement strategies and plans to address them.
  • Share competitive information and suggestions for countering competitors with colleagues.
  • Maintain thorough knowledge of customers' support for competitive products and services, and develop plans to differentiate J&J and competitive offerings to influence customer preference toward J&J offerings.
  • Manage accounts receivable, operating expenses, transportation, advertising and promotion, entertainment, and travel judiciously while ensuring sustainable productivity in the assigned territory.
  • Seek prior approval for budget variations.
  • Ensure team compliance with sample-issue and coordination guidelines.
  • Agree expense budgets and guidelines with the immediate manager.
  • Plan sample and expense utilization to optimize usage while remaining within budget.
  • Identify specific actions to improve job performance in specific areas.
  • Participate in nominated training programs.
  • Use active self-learning strategies to maintain knowledge.
  • Make a focused effort to achieve high performance in knowledge tests and competency assessments related to training.
  • Effectively apply new learning on the job.
  • Maintain a responsible and ethical approach while pursuing business outcomes.
  • Conduct business within the ethics and values expressed in the Credo.
  • Maintain customer relationships based on high ethical standards.
Desired Qualifications
  • A management degree is an added advantage.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

7%

1 year growth

-1%

2 year growth

-1%
Associated Press
Oct 27th, 2026
Pomerantz investigates Johnson & Johnson after 5.73% share drop on talc charges and MedTech miss

Pomerantz LLP is investigating whether Johnson & Johnson (J&J) and some of its officers or directors engaged in securities fraud or other unlawful business practices. The law firm advises affected investors to contact Danielle Peyton at [email protected]. On October 13, 2026, J&J reported third-quarter GAAP net earnings of $210 million, or $0.09 per share. Multi-billion dollar special charges tied to its talc litigation settlement weighed on the result. Its MedTech segment grew only 2.5% to $8.64 billion, a second straight revenue miss. J&J cited pricing constraints in China and disruption in the Middle East. The stock fell $15.12, or 5.73%, to close at $248.61 that day.

Yahoo Finance
Oct 27th, 2026
J&J sees $34.7M net ETF outflow, extending selling streak to four days

ETFs sold a net $34.7 million of Johnson & Johnson stock on Friday, October 23, extending a four-day run of net selling. SPY led the move, cutting $34.6 million, or 0.44% of its stake. XLV sold $24.6 million and DIA $6.3 million. More funds bought than sold, with 26 ETFs adding shares and 17 cutting them, but their purchases were smaller. Net outflows were $55.2 million on October 22, $54.1 million on October 21, and $19.8 million on October 20. A net inflow of $38.1 million came on October 19. Johnson & Johnson has a market cap of $641.1 billion. It reported $99.35 billion in trailing-12-month revenue, up 7.0% over one year.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 23rd, 2026
Smith & Nephew's $22B talks to buy J&J's orthopaedics unit collapse over who would lead

Smith & Nephew's merger talks with Johnson & Johnson (J&J) over its orthopaedics unit collapsed over who would lead the combined company, the Financial Times reported. The sides had reportedly agreed on the main financial terms and the deal structure. J&J wanted Namal Nawana, who runs its orthopaedics unit and formerly led Smith & Nephew, to lead the business. Smith & Nephew wanted current chief executive officer Deepak Nath to stay. Smith & Nephew's offer valued J&J's hip and knee unit at up to $22 billion, almost double its own market value. J&J shareholders would have owned 50.1% of the combined company. J&J is leaning toward spinning off the unit as DePuy Synthes, targeting mid-2027. Reuters reported the unit sought around $20 billion and drew private equity interest. Both companies declined to comment.

Yahoo Finance
Oct 23rd, 2026
ETFs sell $54.1M of Johnson & Johnson, extending two-day selling streak

ETFs sold a net $54.1 million of Johnson & Johnson (JNJ) shares on Wednesday, extending a two-day run of net selling. Twenty-five funds cut their holdings, 24 added shares, and 153 held steady. The Health Care Select Sector SPDR (XLV) led the selling, cutting 153,134 shares worth $39.5 million. The iShares Core S&P 500 ETF (IVV) sold $11.5 million, and the iShares MSCI USA Momentum Factor ETF (MTUM) sold $5.4 million. Tuesday saw net selling of $20.0 million, after net buying of $38.1 million on Monday and $84.4 million on October 16. JNJ has a market cap of $644.9 billion and has returned 31.39% year to date.